San Diego – November 3, 2016 – Cooley advised the underwriters on Ascendis Pharma’s $136.4 million follow-on offering.
J.P. Morgan, BofA Merrill Lynch and Credit Suisse acted as joint book-running managers for the offering. Wedbush PacGrow acted as a co-manager for the offering.
Ascendis (NASDAQ: ASND) is a biopharmaceutical company applying its TransCon technology to develop a pipeline of sustained release prodrug therapies with best-in-class profiles to address large markets with significant unmet medical needs.
Cooley advised Ascendis on its $124 million IPO in 2015.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.